Latest California Healthline Stories
¿Ponerse el refuerzo ahora o esperar? Muchos se preguntan cómo navegar la próxima ola de covid
Aproximadamente el 70% de los estadounidenses de 50 años o más que recibieron una primera vacuna de refuerzo contra covid, y casi la misma cantidad de personas de 65 años o más, no han recibido un segundo, según datos de los CDC.
A Free-for-All From Readers and Tweeters, From Medical Debt to Homelessness
KHN gives readers a chance to comment on a recent batch of stories.
Vaccine and Testing Delays for Monkeypox Echo Failures in Early Covid Response
Public health officials say monkeypox is not as dangerous as covid and can be handled well with current treatments and if those at risk use caution. But the rollout of vaccines has been slow and led to angst among some at-risk people.
Igual que con covid, atraso en pruebas y vacunas para la viruela del simio
Los casos de la viruela del simio siguen aumentando, pero la respuesta sanitaria es lenta: escasean las pruebas y las dosis de la vacuna que puede prevenir la infección.
‘Free’ Screening? Know Your Rights to Get No-Cost Care
Even a decade in, the Affordable Care Act’s recommendations to simply cover preventive screening and care without cost sharing remain confusing and complex.
How Pfizer Won the Pandemic, Reaping Outsize Profit and Influence
The drugmaker has the best-selling vaccine to prevent covid and the most effective drug to treat it. Its success has overshadowed the government’s covid-fighting strategy.
‘My Body, My Choice’: How Vaccine Foes Co-Opted the Abortion Rallying Cry
Anti-vaccine advocates discovered a catchy, succinct, and potent slogan. Its unlikely source: the abortion rights movement.
Cómo Pfizer le ganó a la pandemia, alcanzando influencia y ganancias descomunales
Su éxito en el desarrollo de medicamentos contra covid le ha dado a la farmacéutica un peso inusual en la determinación de la política de salud de Estados Unidos. Algo que preocupa a expertos.
KHN’s ‘What the Health?’: A World Without ‘Roe’
The Supreme Court’s decision overturning Roe v. Wade has created far more questions than it has answered about the continued legality and availability of abortion, as both abortion rights supporters and anti-abortion activists scramble to put their marks on policy. Meanwhile, Congress completes work on its gun bill and the FDA takes up the problem of the next covid-19 booster. Margot Sanger-Katz of The New York Times, Sarah Karlin-Smith of the Pink Sheet, and Victoria Knight of KHN join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHN’s Angela Hart, who reported and wrote the latest KHN-NPR “Bill of the Month” episode about two identical eye surgeries with very different price tags.
What You Need to Know About Monkeypox
For now, monkeypox poses a low risk to the U.S. public, but it could become a problem if the spread is left unchecked. Here’s what everyone should know about it.